CA2547863A1 - Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie - Google Patents

Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie Download PDF

Info

Publication number
CA2547863A1
CA2547863A1 CA002547863A CA2547863A CA2547863A1 CA 2547863 A1 CA2547863 A1 CA 2547863A1 CA 002547863 A CA002547863 A CA 002547863A CA 2547863 A CA2547863 A CA 2547863A CA 2547863 A1 CA2547863 A1 CA 2547863A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
pyridin
ylethyl
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002547863A
Other languages
English (en)
Inventor
Pia Knuuttila
Harri Salo
Jussi Tomperi
Siegfried Wurster
Anna-Marja Hoffren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Juvanita Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20031824A external-priority patent/FI20031824A0/fi
Application filed by Juvanita Pharma Ltd Oy filed Critical Juvanita Pharma Ltd Oy
Publication of CA2547863A1 publication Critical patent/CA2547863A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002547863A 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie Abandoned CA2547863A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50907303P 2003-12-12 2003-12-12
FI20031824A FI20031824A0 (fi) 2003-12-12 2003-12-12 Uusia yhdisteitä ja niiden käyttö terapiassa
FI20031824 2003-12-12
US60/509,073 2003-12-12
PCT/FI2004/000750 WO2005056520A1 (fr) 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie

Publications (1)

Publication Number Publication Date
CA2547863A1 true CA2547863A1 (fr) 2005-06-23

Family

ID=34680375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002547863A Abandoned CA2547863A1 (fr) 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie

Country Status (4)

Country Link
EP (1) EP1692099A1 (fr)
JP (1) JP2007513928A (fr)
CA (1) CA2547863A1 (fr)
WO (1) WO2005056520A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
JP2011522813A (ja) * 2008-06-04 2011-08-04 アストラゼネカ アクチボラグ 低分子レプチン受容体修飾因子
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (fr) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation
AU2009322167B2 (en) 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
US8465725B2 (en) 2009-06-15 2013-06-18 Molecular Insight Pharmaceuticlas, Inc. Process for production of heterodimers of glutamic acid
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
CN105025933B (zh) 2013-01-14 2019-03-26 分子制药洞察公司 三嗪类放射性药物和放射性显影剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492370B1 (en) * 1998-03-26 2002-12-10 Santen Pharmaceutical Co., Ltd. Urea derivatives and pharmaceutical compositions thereof
RU2288739C2 (ru) * 2001-01-12 2006-12-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик, С.А.С. Фармацевтические композиции, которые подавляют сосудистую пролиферацию, и способ их применения
US7019109B2 (en) * 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs

Also Published As

Publication number Publication date
EP1692099A1 (fr) 2006-08-23
WO2005056520A8 (fr) 2005-09-15
WO2005056520A1 (fr) 2005-06-23
JP2007513928A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
JP6861858B2 (ja) Ｓｓａｏ阻害剤
AU758202B2 (en) Novel thyroid receptor ligands and method II
CN112292375A (zh) 取代的烷氧基吡啶基吲哚磺酰胺类
WO2008110008A1 (fr) Dérivés d'amide utilisés comme inhibiteurs du canal calcique
KR20190084063A (ko) Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
CN109879877B (zh) 一种可降解plk1和brd4蛋白的化合物及其应用
CA2493660A1 (fr) Nouveaux composes
CA2287293A1 (fr) Agonistes de la stomatostatine
UA85842C2 (uk) Похідні бензімідазолу як інгібітори ванілоїдного рецептора 1 (vr1)
JP2007513181A (ja) 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070043104A1 (en) UII-modulating compounds and their use
SK15812000A3 (sk) Inhibítory enzýmu na premenu endotelínu
CA2547863A1 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
EP1675824B1 (fr) Agonistes et antagonistes selectifs du recepteur de la somatostatine 1 et/ou 4
US20100048549A1 (en) Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
KR20020013942A (ko) 아미노벤조산 유도체
EP1678196B1 (fr) Sulfonylamino-peptidomimetiques actifs sur les sous-types 4 (sstr4) et 1 (sstr1) du recepteur de somatostatine
EP4365170A1 (fr) Composé amide et son utilisation
US20100004339A1 (en) Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
WO2005033068A1 (fr) Recepteur 1 et/ou 4 de somatostatine, agonistes et antagonistes selectifs
EP1864995B1 (fr) Cyclopeptides rgd beta-lactamiques contenant des tours gamma
EP1544201B1 (fr) Nouveaux derives de cycloalcanodiones, leur procede de preparation et leurs applications pharmacologiques
ES2352736T3 (es) Agonistas y antagonistas selectivos del receptor de somatostatina 1 y/o 4.
US20040014676A1 (en) SRC kinase inhibitors useful for treating osteoporosis
JPH08504779A (ja) 新規な非環式、硫黄含有ペプチド

Legal Events

Date Code Title Description
FZDE Dead